The newly independent firm will continue to invest in diagnostics by bringing its menu of PCR tests for infectious diseases to the US and other markets, among other objectives.
The firm sold more than 4.9 million shares of common stock at $15 per share, raising $73.7 million to expand its commercial operations and grow its technology.
The firm plans to use the proceeds to expands its commercial operations, expand its existing technology, and support the launch of its new platform.
Calyxt increased the number of shares it intends to float, but slashed its offering price in half from the middle of a previously disclosed range.
The company, a division of BGI Group, sold 40.1 million shares at RMB 13.64 per share for a total of RMB 547 million ($80.6 million) in the offering.
The firm began offering its common shares on Wednesday at $6 per share on the Nasdaq. Gross proceeds from the IPO were $7.1 million.
The molecular diagnostics firm said in an amended prospectus that it plans to offer 1.3 million shares of its common stock at between $6.35 and $6.75 per share.
Samsung Biologics debuted last week in Seoul with the largest IPO in South Korea in years, according to the Associated Press.
The IPO amount is about half of what the company's competitors, Editas Medicine and Intellia Therapeutics, raised in their own IPOs earlier this year.
In a filing with the US Securities and Exchange Commission, the company said it intends to sell up to $90 million in common stock on the Nasdaq.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.